Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial.

EJHaem · 2022 · PMC9713042 · PMID 36467814

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

A numerical trend was seen towards improved EFS and PFS with ibrutinib+R‐CHOP versus placebo+R‐CHOP in patients with MYC ‐high/ BCL2 ‐high co‐expression.

also in 1,012 other papers

did not reach statistical significanceno p-value reported

Similar trends in EFS, PFS and OS were also observed in patients aged <60 years in the ABC subpopulation, although these did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.